CandlesenseCandlesense
TEVA•benzinga•

UPDATE: Teva Cuts FY22 Sales Guidance From $15.6B-$16.2B To $15.4B-$16B vs $15.97B Estimate, Reaffirms Adj. EPS Guidance $2.40-$2.60 vs $2.51 Est.

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 3, 2022 by benzinga

← Back to TEVA News
    UPDATE: Teva Cuts FY22 Sales Guidance From $15.6B-$16.2B To $15.4B-$16B vs $15.97B Estimate, Reaffirms Adj. EPS Guidance $2.40-$2.60 vs $2.51 Est. | TEVA Stock News | Candlesense